Comparative Effectiveness Research of Electroacupuncture and TENS in Patients With Rheumatoid Arthritis

Not Applicable

Recruiting

• Conditions: Arthritis, Rheumatoid

• Registration Number: NCT04521998
• Lead Sponsor: China Medical University Hospital

Brief Summary

The aim of this pilot study is to compare the effectiveness of electroacupuncture or transcutaneous electrical nerve stimulation in reducing the tenderness in the patients with rheumatoid arthritis. The study adopted a pragmatic, randomized, patient-centered approach to investigate the effectiveness of clinical symptoms and quality of life.

Detailed Description

A total of 80 volunteers of patients with rheumatoid arthritis will be recruited from the Chinese medicine or Western medicine clinics in China Medical University Hospital and Dalin Tzu-Chi Hospital. These patients will be randomized to receive electroacupuncture (40 participants) or transcutaneous electrical nerve stimulation (40 participants) treatment two sessions per week and for 10 treatments in total.

The investigators expect that electroacupuncture or transcutaneous electrical nerve stimulation can reduce the severity of pain in the patients with rheumatoid arthritis. The effectiveness of electroacupuncture or transcutaneous electrical nerve stimulation can be detected by visual analogue scale, simplified disease activity index, and disease activity score and be used to improve the clinical symptoms and quality of life.

Study Timeline

• Study Start: 2020-08-04
• Study First Submitted: 2020-08-16
• Study First Submitted QC: 2020-08-19
• Study First Posted: 2020-08-21
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-18
• Last Update Posted: 2022-07-20
• Primary Completion: 2025-09-30
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• 20-70 years old
• Met the American College of Rheumatology criteria (2010) for RA
• Classification of X-ray : Stage I~III
• The participants' RA medication regimen (DMARD, NSAID, steroid)were eligible if they were on a stable dose for at least 3 months before entry into and throughout the study.
• All patients were instructed not to make any changes in their background therapies during the study.
• Intra-articular or pulse steroid were not permitted during the study

Exclusion Criteria

• Be treated with biological agents, such as antagonist of TNF-alpha, IL-6, Jak, and CD20 mono antibody in the last 3 months
• Having history of serious drug allergy
• Pregnancy or breastfeeding
• Bleeding or coagulation disorders
• Localized skin infections
• Uncontrolled or ill-controlled blood pressure with diastolic pressure≥110 mmHg
• Any other acupuncture treatment or herbal medication for RA within 2 weeks before screening
• needle phobia
• Intra-articular corticosteroid or pulse steroid within 4 weeks preceding the study
• Any severe chronic or uncontrolled comorbid disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Morning stiffness(scoring range 0~10 and lasting time : min/day)	baseline, week 5, and week 9	Changes from baseline to end of intervention and 4 weeks after intervention completed

Secondary Outcome Measures

Name	Time	Method
Simplified disease activity index (scoring range 0.0 ~ 86.0)	baseline, week 5, and week 9	Changes from baseline to end of intervention and 4 weeks after intervention completed
Disease Activity Score 28 (scoring range 0.0 ~ 9.4)	baseline, week 5, and week 9	Changes from baseline to end of intervention and 4 weeks after intervention completed
Erythrocyte sedimentation rate	baseline, week 5, and week 9	Changes from baseline to end of intervention and 4 weeks after intervention completed
Clinical Disease Activity Index (scoring range 0.0 ~ 76.0)	baseline, week 5, and week 9	Changes from baseline to end of intervention and 4 weeks after intervention completed
Pain Visual Analogue Scale (scoring range 0 ~ 10)	baseline, week 5, and week 9	Changes from baseline to end of intervention and 4 weeks after intervention completed
C-reactive protein	baseline, week 5, and week 9	Changes from baseline to end of intervention and 4 weeks after intervention completed

Trial Locations

Locations (1)

China Medical University Hospital; 🇨🇳 Taichung, Taiwan